Skip to main content
. 2022 Feb 4;6(3):1025–1037. doi: 10.1182/bloodadvances.2021005954

Figure 4.

Figure 4.

Association of baseline blood biomarkers with response to glofitamab. (A) Box plots show the baseline (pre-obinutuzumab pretreatment [Gpt]) peripheral concentrations of CD3+, CD4+, and CD8+ T cells in relation to the best overall response (BOR) categories, as measured by flow cytometry (n = 75). P values >.05. (B) Box plots represent the baseline (pre-Gpt) plasma concentrations of CRP, IL-6, and IL-8 in relation to the BOR categories (n = 72). CRP (P = .004), IL-6 (P = .07), and IL-8 (P = .06) levels were lower at baseline in patients who achieved a CR compared with other response categories (PR, stable disease [SD], progressive disease [PD]).